Imaging3, Inc. Announces Commencement of Trading of Its Common Stock on the OTCQB Under Trading Symbol IGNG
Summary
We view this as a significant step forward for the Company and are especially gratified that we have been able to obtain the OTCQB approximately 10 weeks after our 15c2-11 filing was approved and our stock commenced trading on the OTCPink market after the four-year hiatus caused by our successful Chapter 11 reorganization.The Company’s technology will allow healthcare professionals utilizing Imaging3 lightweight portable devices to view 3D, high resolution images of virtually any part of the human body in real time, even as they are performing procedures.We view this as a significant step forward for the Company and are especially gratified that we have been able to obtain the OTCQB approximately 10 weeks after our 15c2-11 filing was approved and our stock commenced trading on the OTCPink market after the four-year hiatus caused by our successful Chapter 11 reorganization.We believe this will help build momentum as we strive toward our goal of obtaining FDA 510K approval of our technology.”The Company intends to provide ongoing updates of relevant material information to the public in the form of appropriate filings and press releases, all of which will be available on EDGAR, the OTCMarkets website and our Company website, www.imaging3.com.About Imaging3Imaging3, Inc., founded in 1993, has developed a patented medical imaging technology that will produce 3D medical diagnostic images in real time in each of single 3D SafeScan, Continuous 3D Scan and CT SafeScan mode.These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, failure to consummate desired business combinations or transactions, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently, unavailability of financing for the Company or its customers, product malfunction, potential product liability claims, and other factors detailed in reports filed by the Company.Investor Relations Contact:Amato and Partners, LLC90 Park Avenue, 17th FloorNew York, NY 10016admin@amatoandpartners.com Contact Information Imaging3 Dane Medley 800-900-9729 www.imaging3.com Click here to view the list of recent Press Releases from Imaging3 Promote Your Business Press Release Pricing Email this page to a friend